Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors

NCT04344795 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

89

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumor
Colorectal Cancer
Non Small Cell Lung Cancer
Squamous Cell Carcinoma of Head and Neck
Urothelial Carcinoma
Endometrial Cancer
Gastroesophageal Junction Adenocarcinoma
Gastric Adenocarcinoma
Solid Tumors With PIK3Ca Mutation

Interventions

DRUG: TPST-1495 twice daily
DRUG: TPST-1495 once daily or on intermittent schedule
DRUG: Pembrolizumab

Sponsor

Tempest Therapeutics